Specifically, WHI found there was a 54 percent increased risk of death after a colorectal cancer diagnosis when female patients were randomized to combined hormone therapy compared to placebo trials. Although a few number of colorectal cancers resulted from the combined-therapy group, the group was at higher risk of mortality.
Read the abstract on menopausal hormone therapy and CRC.
Read other coverage about colorectal cancer:
– Studies Show Mailed and Electronic Reminders Increase Colorectal Cancer Screening Rates
– Study Suggests Hormone Therapy Could Increase Risk of CRC by Up To 40%
– 10 Recent Studies and Breakthroughs Impacting Gastroenterology/Endoscopy
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.